Rosenfeld R G
Department of Pediatrics, Stanford University School of Medicine, CA 94305.
J Endocrinol Invest. 1989;12(8 Suppl 3):49-51.
In 1983, a multicenter, collaborative, prospective study was begun to investigate the efficacy of human growth hormone (hGH), alone and in combination with oxandrolone, in girls with Turner syndrome. While subjects in the control group grew 3.8 cm/yr (-0.1 SD for untreated Turner patients), subjects receiving hGH alone grew 6.6, 5.4 and 4.6 cm/yr in years 1-3, respectively (+3.1, +2.0, +1.4 SD). Subjects in the combination therapy group grew 9.8, 7.4 and 6.1 cm/yr (+6.6, +4.3, +3.0 SD). Turner subjects in both treatment groups showed increased in Bayley-Pinneau predicted adult heights and in Turner projected adult heights.
1983年，一项多中心、协作性的前瞻性研究启动，旨在调查人生长激素（hGH）单独使用以及与氧雄龙联合使用对特纳综合征女孩的疗效。对照组受试者每年生长3.8厘米（未治疗的特纳患者为-0.1标准差），而单独接受hGH治疗的受试者在第1至3年分别每年生长6.6厘米、5.4厘米和4.6厘米（+3.1、+2.0、+1.4标准差）。联合治疗组的受试者每年生长9.8厘米、7.4厘米和6.1厘米（+6.6、+4.3、+3.0标准差）。两个治疗组中的特纳受试者在贝利-平诺预测成人身高和特纳预测成人身高方面均有所增加。
